- Home
- SBMT vs KZIA Comparison
SBMT vs KZIA Comparison
Compare SBMT & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SBMT | KZIA |
|---|---|---|
| Founded | 2020 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 242.1M | 186.7M |
| IPO Year | 2026 | 2002 |
Fundamental Metrics
Financial Performance| Metric | SBMT | KZIA |
|---|---|---|
| Price | $7.38 | $7.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $20.13 | ★ $28.33 |
| AVG Volume (30 Days) | 89.9K | ★ 261.5K |
| Earning Date | 11-05-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $23.42 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.75 | $4.86 |
| 52 Week High | $9.48 | $17.40 |
Technical Indicators
Market Signals| Indicator | SBMT | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 40.84 | 28.65 |
| Support Level | $7.27 | $6.82 |
| Resistance Level | $7.59 | $8.18 |
| Average True Range (ATR) | 0.38 | 0.63 |
| MACD | -0.13 | -0.13 |
| Stochastic Oscillator | 19.50 | 20.05 |
Price Performance
Historical ComparisonAbout SBMT Silver Bow Mining Corp. Common Shares
Silver Bow Mining Corp is engaged in the acquisition, exploration, and development of mineral resource properties in Butte, Montana, USA. The Company's primary business objective is to identify and evaluate prospective properties with the potential for future extraction and commercialization.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.